Shots: The P-III KEYNOTE-119 study results involves assessing of Keytruda (pembrolizumab, 200mg) as monothx. vs CT (capecitabine/eribulin/gemcitabine/vinorelbine) for the 2L/3L treatment in 622 patients in ratio (1:1) with metastatic triple-negative […]readmore
